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Purpose: Longitudinal data on the effect of time and environmental conditions on physical
activity (PA) among COPD patients are currently scarce, but this is an important factor in the
design of trials to test interventions that might impact on it. Thus, we aimed to assess the
effect of time and climate conditions (temperature, day length and rainfall) on progression of
PA in a cohort of COPD patients.
Patients and methods: This is a prospective, multicenter, cohort study undertaken as part
of the EU/IMI PROactive project, in which we assessed 236 COPD patients simultaneously
wearing two activity monitors (Dynaport MiniMod and Actigraph GT3X). A multivariable
generalized linear model analysis was conducted to describe the effect of the explanatory
variables on PA measures, over three time points (baseline, 6 and 12 months).
Results: At 12 months (n=157; FEV1% predicted=57.7±21.9) there was a signiﬁcant
reduction in all PA measures (Actigraph step count (4284±3533 vs 3533±293)), Actigraph
moderate- to vigorous-intensity PA ratio (8.8 (18.8) vs 6.1 (15.7)), Actigraph vector magni-
tude units (374,902.4 (265,269) vs 336,240 (214,432)), MiniMod walking time (59.1 (34.9)
vs 56.9 (38.7) mins) and MiniMod PA intensity (0.183 (0) vs 0.181 (0)). Time had a
signiﬁcant, negative effect on most PA measures in multivariable analysis, after correcting
for climate factors, study center, age, FEV1% predicted, 6MWD and other disease severity
measures. Rainfall was the only climate factor with a negative effect on most PA parameters.
Conclusion: COPD patients demonstrate a signiﬁcant decrease in PA over 1 year follow-up,
which is further affected by hours of rainfall, but not by other climate considerations.
Keywords: physical activity, chronic obstructive pulmonary disease, elapsed time, climate
Introduction
COPD is a chronic, debilitating disorder.1 Although progressive airﬂow limitation is
the diagnostic feature of this disease, several other manifestations, such as exer-
tional dyspnea, reduced exercise capacity, muscle weakness, reduced physical
activity (PA) and poor health-related quality of life, are of major clinical importance
for the COPD patient and may also worsen with time.2 Reduced daily PA is
observed early in the course of the disease,3,4 has a range of causes and conse-
quences, including an association with several systemic components of COPD5,6
and is a strong predictor of exacerbation rate, hospital admission and mortality.7
However, published data on longitudinal studies which evaluated changes in PA
with time relative to other features of the disease are currently limited8–11 and are
not without limitations. In a single-center study Waschki et al established that PA
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declines with time,9 evaluating a mixed population of
COPD and chronic bronchitis patients, while in another
longitudinal study with similar results, more than 90% of
participants were male.11 Moreover, most published stu-
dies assessed changes in PA after a relatively long follow-
up period of more than 2 years,9–11 during which several
other disease features had also worsened.
Previous data indicate that weather conditions may
be an important factor to consider when assessing the
variability of daily PA. In a large systematic review
looking at approximately 300,000 healthy individuals
(adults, adolescents and children) from eight different
countries, PA varied with seasonality and was found to
be higher in the summer months and signiﬁcantly lower
during the winter.12 However, patterns of PA are not
identical in health and disease, especially when exercise
induces disease-speciﬁc symptoms.13 Currently, evi-
dence of the speciﬁc effect of environmental conditions
on PA among COPD patients is limited.14–17 In these
studies, season and temperature were established as the
most signiﬁcant climate predictors of daily step count.
Nevertheless, the relatively small patient cohort,12 wide
variations in the follow-up period14 and the lack of
objective indices to deﬁne seasons15,16 are some of the
factors which limit the interpretation of these results.
Moreover, all these studies14–16 were single-center stu-
dies, and therefore the important question of the effect
of geographical area on PA variation among COPD
patients living in different countries is currently
unknown.
Against this background we conducted an analysis of
data obtained during a prospective, multicenter, longitudi-
nal study, undertaken as part of the EU/IMI PROactive
project,18 in order to assess the change in PA levels over
time, deﬁned by three time point measurements (at base-
line, 6 and 12 months), corrected for the potential effect of
climate variation (as deﬁned by weekly average of day
length, temperature and rainfall) among COPD patients.
We hypothesized that PA would decline with time, being
lower at the end of the 12-month study period and that it
would be affected by climate, being lower in conditions of
cooler temperature, increased rainfall and shorter day
length. This is important both for understanding the nat-
ural history of COPD and particularly for trial design
when considering the size, setting and duration of studies
with PA as an outcome measure, especially in trials with a
multicenter protocol.
Materials and methods
Study population
The study population was recruited from ﬁve European cen-
ters as part of the PROactive study (Royal Brompton Hospital,
London UK: ELEGI Colt Institute, Edinburgh, UK; KU
Leuven, Belgium; First Department of Respiratory Medicine,
National & Kapodistrian University of Athens Medical
School, Greece; Department of General Practice, University
Medical Center Groningen, Netherlands).18 All had a clinical
history compatible with COPD, spirometric evidence of
chronic airﬂow limitation (post bronchodilation FEV1 to
FVC ratio<0.7), and were clinically stable (have not used
systemic antibiotics, systemic corticosteroids or being hospi-
talized) for a minimum of 4 weeks prior to entering the study.
Patients who had co-morbidities which would interfere with
their movement (e.g. orthopedic disorders or neuromuscular
disease), respiratory diseases other than COPD (e.g. asthma),
cognitive impairment, were excluded. All patients gave writ-
ten informed consent for participation in the study, and the
study protocol received ethical approval from the respective
research ethics committees (Lothian Regional Ethics
Committee, UK; UZ Leuven Medical Ethics Committee,
Belgium; University Hospital Ethics Committee “Sotiria”
Chest General Hospital Athens, Greece, University Medical
Center Ethics Committee University of Groningen, The
Netherlands) as well as local site-speciﬁc approval. We also
conﬁrm that this study was conducted in accordance with the
Declaration of Helsinki. Some data from this cohort have been
previously published.19,20 Application for access to deidenti-
ﬁed patient data can be made to the PROactive consortium via
the authors.
Study protocol and measurements
Study design
This was a prospective cohort study with measurements at
baseline, 6 and 12 months follow-up. Details of the study
protocol and assessments are available on: www.clinical
trials.gov (NCT01388218).18 Baseline measures included
anthropometrics, spirometry, plethysmographic lung volumes,
quadriceps maximal voluntary contraction (QMVC), COPD
Assessment Test (CAT),21 Hospital Anxiety and Depression
scale (HAD),22 Chronic COPD Questionnaire (CCQ),23 as
well as 6MWD assessed according to guidelines,24 which
included a practice walk.
PA monitoring
Patients were required to wear simultaneously two PA
monitors previously validated in people with COPD,25,26
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the Dynaport MiniMod (McRoberts BV, the Hague, the
Netherlands) and Actigraph GT3X (Actigraph, Pensacola,
FL, USA).26 Both monitors are trunk-worn triaxial accel-
erometers; the MiniMod was worn in the small of the
back; the Actigraph was worn at the right hip.
Baseline assessment involved 2 consecutive weeks of
PA monitoring. Patients were instructed not to wear the
monitors at night when asleep or while bathing or swim-
ming. Follow-up was conducted at 6 and 12 months from
baseline, but with only 1 week of activity monitoring; this
shorter period of monitoring was decided as a result of work
previously published by the PROactive consortium.25 The
measures of PA recorded by the Actigraph were step count,
moderate-intensity to vigorous-intensity PA ratio (mvpa)
and vector magnitude units (VMU) (that is the vectorial
sum of activity counts in three orthogonal directions) per
day, while the MiniMod recorded step count, time spend in
walking (walktime), PA intensity (measured in metabolic
equivalents) and VMU per day.
Weather data
Data speciﬁc to the time periods during which patients
were studied, as well as to their location, were provided
by the UK Meteorological Ofﬁce (https://www.metofﬁce.
gov.uk). The Meteorological Ofﬁce provided weather
information for all European centers. These data com-
prised daily highest temperature and information on num-
ber of hours of sunlight and hours of rainfall (any hour in
which there was any rainfall at all was counted), per day.
Daily weather data were available for every day of activity
monitoring collected. Unfortunately, data on daily hours of
sunshine were not available for two of the centers (Leuven
and Groningen) so these centers could not be included in
that analysis.
Statistical analysis
The following guidelines were used when processing the PA
data: 1) at least 10 hrs of activity data for a day were required
for that day to be included in the analysis, 2) patients who did
not participate in all three time points (baseline, 6 and
12 months) were excluded from ﬁnal analysis and 3) data
were analyzed on a patient and not on a day-by-day basis,
for each time point (that is we summarized data on PA mea-
surements and on climate variable measurements, for each
study period). All analyses were carried out using IBM
SPSS Version 19 for Windows XP. Continuous variables are
presented as mean value ±1 SD or as median value (inter-
quartile range) depending on the normality or not of their
distribution, while categorical variables are presented as abso-
lute and % value. Normality of distribution of values was
assessed using the Shapiro–Wilk normality test, while Q-Q
plots were used for visual conﬁrmation of distribution of data.
One-way ANOVA or Kruskal–Wallis test was applied to
compare normally or non-normally distributed quantitative
variables across different geographical sites at baseline.
Values of PA measures and 6MWD were also compared
between baseline, 6 and 12 months using: 1) the repeated
measures ANOVA for normally distributed variables; equality
of the variances of differences was tested utilizing the
Mauchly’s test of sphericity and the Huynh-Feldt correction
was used when assumption of sphericity was violated, while
the Bonferroni post-hoc test was applied for pairwise compar-
isons between groups, and 2) the Friedman test for non-nor-
mally distributed variables. Τhe pairwise comparisons were
further conducted using the Wilcoxon rank test and the
Bonferroni correction for multiple comparisons. The bivariate
association between climate variables and each PA measure
was plotted utilizing generalized additive models; temperature
was linearly associated with all PAmeasures, while for rainfall
and day length, appropriate cutoff points were determined
based on the curves of the spline lines. Further analysis of
results was set out a priori as follows: the null hypothesis was
that there is no difference in PA measures between baseline,
6 and 12months follow-up, when corrected for age at baseline,
climate conditions, study site, lung function and 6MWD. To
test this hypothesis, a generalized linear model analysis was
applied with each PA measure as the dependent (response)
variable.26 The constructed models tested visit, study site,
baseline measurements (age, FEV1% predicted, residual
volume (RV) to total lung capacity (TLC) ratio% predicted,
6MWD, QMVC) and climate variables of each time point
(temperature, day length, rainfall) as potential predictors
(explanatory variables), simultaneously.27 The Akaike's
Information Criterion and the −2 Log-Likelihood function
were used to select the best model ﬁt.28 The gamma distribu-
tion was chosen to ﬁt PA measures distribution, while the link
function which was ﬁnally selected was Log, so the μi of each
response variable could be expressed as: μi = g−1(ηi) = eηi. A
level of p<0.05 was considered signiﬁcant for all analyses.
Results
Study population
A total of 236 COPD patients (67.4±8.4 years old;
57±20.5% FEV1% predicted; 67.8% male) were recruited
from ﬁve different European centers. COPD patients
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represented a wide range of disease severity: 15% (n1=34)
were GOLD stage I, 46% (n2=108) were GOLD stage II,
30% (n3=71) were GOLD stage III and 9% (n4=22) were
GOLD stage IV. The baseline population characteristics
and the baseline climate conditions, along with a break-
down by center are presented in online Table S1. However,
not all patients completed the study (Figure 1). Table 1
presents baseline characteristics of the ﬁnal study popula-
tion, that is of the 157 patients (67.2±7.8 years old;
FEV1=57.7±21.9% predicted; 75.8% male) who ﬁnally
completed both the 6 and the 12 months follow-up and
were, thus, included in further analysis. Several baseline
differences were noted between centers. For example,
patients in Athens, who were recruited from a hospital
outpatient clinic, had lower FEV1% predicted, QMVC
and 6MWD, compared to patients in most of the other
centers. Patients in Edinburgh, on the other hand, were
older and had higher QMVC, compared to the rest.
Patients in Leuven had higher baseline step counts and
other PA measures, while in Groningen, where a larger
proportion of patients came from primary care, patients
were younger and presented with higher 6MWD, com-
pared to other centers. Baseline climate conditions were
also signiﬁcantly different between the centers, with
longer day length, higher temperature, more sunshine
hours and much less hours with rainfall in Athens than
the rest (Table 1). Overall, gender ratio, body mass index
(BMI), RV/TLC% predicted, HAD anxiety (A), HAD
depression (D), CAT and CCQ scores were the only base-
line variables found to be similar across all study sites
(Table 1).
Changes in PA levels with time
Univariate analysis indicated that PA declined with time.
All PA measures, apart from PA intensity, were signiﬁ-
cantly higher at baseline, compared both to 6 months
and to 12 months follow-up (Table 2). For instance, the
median number of steps had dropped by approximately
Figure 1 Study ﬂowchart.
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750 steps (Actigraph) after 1 year. Intensity, on the other
hand, was found to decline signiﬁcantly at 12 months
follow-up, but it was similar, compared to baseline, at
the 6 months follow-up. For all activity measures,
recorded by both activity monitors, univariate compar-
ison between baseline, 6 months follow-up and 12
Table 1 Baseline characteristics of patients who completed follow up and separated by center
Variable Total population
(N=157)
Athens
(N1=37)
Edinburgh
(N2=25)
Leuven
(N3=45)
London
(N4=30)
Groningen
(N5=20)
p-value
Recruitment site Hospital/rehabilitation/
primary care
Hospital Hospital Rehabilitation Hospital Primary care NA
Age (years) 67.2±7.8 66.2±8.3 71±7.1 66.4±6.3 68.8±8.4 63.8±8.9 0.019
Male/female 119:38 27:10 20:5 36:9 21:9 15:5 0.846
BMI (kg/m2) 26.7±4.9 26.7±6.1 27.3±4.3 27.1±4.7 25.5±5 26.8±3.3 0.684
FEV1% 57.7±21.9 48.3±15.5 61.6±24.2 64.6±22 54±25.2 60.1±18.4 0.009
RV/TLC% 50.2±11.9 50.9±13.6 47.9±9.5 50.3±13 52.5±9.3 47.8±11.7 0.576
6MWD (m) 449.1±124.1 381.5±73.2 424.6±119.2 502±142.7 440.5±120.3 497.7±100.6 <0.001
QMVC (kg) 33.4±32.4 27.9±7.8 41±11.1 35.1±10 30.6±9.5 34.2±15.9 <0.001
AG steps 4284 (3533) 3807 (3585) 3338 (2615) 5166 (4216) 4207 (3552) 3784 (3710) 0.238
AG mvpa 8.8 (18.8) 7.8 (18.8) 7.2 (11.4) 9.9 (20.6) 12.1 (29.3) 7.5 (10.7) 0.663
AG VMU 374902.4 (265269) 309289.1
(194928)
322229.6
(161516)
453780
(238837)
356768.9
(284389)
385016.8
(228490)
0.178
MM steps 4690 (3708) 4135 (3486) 4070 (2554) 5774 (4418) 3583 (3600) 4733 (4231) 0.005
MMwalktime (mins) 59.1 (34.9) 54.3 (40.7) 52 (19.2) 75.6 (42) 48 (43.5) 57.1 (47.7) 0.003
MM intensity (g) 0.2 (0) 0.2 (0) 0.2 (0) 0.2 (0) 0.2 (0) 0.2 (0) 0.080
MM VMU 286039.6 (237721) 234813.2
(245045)
215748
(122400)
364976.9
(331440)
297922.1
(230476)
332468.7
(270081)
0.057
Temp (°C) 17.1 (7.5) 20.7 (14) 14.9 (4.8) 16.1 (6.9) 19.4 (7.2) 12.9 (5) <0.001
Sunshine (hrs) 4.7 (3.5) 6.5 (4) 2.6 (1.5) - 4.3 (2.7) - <0.001
Rainfall (hrs/day) 0.2 (1.2) 0 (0) 1.4 (1.9) 0.3 (1.3) 0.3 (1) 0.1 (0.9) <0.001
Day length (mins) 640.2 (158.4) 662.3 (117.5) 647.2 (191.6) 647.4 (259) 694.1 (211) 589.3 (80.8) <0.001
HAD A$ 5 (7) 6 (7) 6 (4.5) 4.5 (6.8) 5 (6.3) 3 (4.8) 0.265
HAD D$ 4 (5) 5 (4.5) 35 (4.5) 4 (5.8) 4 (4.5) 2.5 (5.5) 0.176
CAT$ 13 (10.5) 14 (8.5) 12 (9) 14 (18) 11 (16) 10.5 (9.5) 0.832
CCQ$ 1.7 (1.6) 1.6 (1.4) 1.6 (1.6) 1.4 (1.2) 2.1 (2.2) 1.2 (1.9) 0.473
Note: ~Male/female represented as frequencies with the result of Chi-squared test presented. $Although these data are presented, there were several missing values so
they were not used in further analysis.
Abbreviations: BMI, body mass index; RV/TLC%, ratio of residual volume to total lung volume percentage predicted; QMVC, quadriceps maximal voluntary contraction;
AG, Actigraph GT3X monitor; MM, Dynaport MiniMod monitor; mvpa, moderate to vigorous physical activity; VMU, vector magnitude units; ln, natural logarithm; °C,
degrees centigrade; HAD A, Hospital Anxiety and Depression Scale, Anxiety score; HAD D, Hospital Anxiety and Depression Scale, Depression score; CAT, COPD
Assessment Tool; CCQ, Clinical COPD Questionnaire.
Table 2 Change of physical activity measures and 6MWD with time for patients who completed follow-up, in univariate analysis
Variable Baseline 6 months 12 months p-Value^
FEV1 (% predicted) 57.7±21.9 57.2±22.6 57.8±22.2 0.983
6MWD (m) 449.8±127.2 430.8±132.3 440.5±131.8 0.839
AG steps 4284 (3533) 3594 (3212) 3533 (2930) <0.001
AG mvpa 8.8 (18.8) 7.4 (17.4) 6.1 (15.7) <0.001
AG VMU 374,902.4 (265,269) 330,420 (223,152) 336,240 (214,432) <0.001
MM steps 4690 (3708) 4264 (3378) 4359 (3425) 0.001
MM walktime (mins) 59.1 (34.9) 53.2 (34.4) 56.9 (38.7) 0.001
MM intensity (g) 0.183 (0) 0.183 (0) 0.181 (0) <0.001
MM VMU 286,039.6 (237,721) 265,253.2 (218,109) 259,447.4 (199,472) <0.001
Note: ^p-Value for comparisons between baseline and 12-month follow-up.
Abbreviations: AG, Actigraph GT3X monitor; mvpa, moderate to vigorous physical activity; MM, Dynaport MiniMod monitor; VMU, vector magnitude units.
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months follow-up, indicated that change in PA levels
with time was similar across centers (p>0.05), besides
the differences that had been noted at baseline (data not
shown). Over the course of follow-up, RV/TLC % pre-
dicted increased signiﬁcantly (baseline: 50.82±11.43 vs
6 months: 58.79±22.92 vs 12 months: 59.62±23.63;
p<0.001), while the rest of parameters (FEV1% pre-
dicted, QMVC and CAT score) remained unchanged,
compared to baseline. 6MWD was also unchanged
over the 12-month period.
In multivariable analysis, time remained an independent
predictor for most PA measurements, but its effect was
signiﬁcant only when baseline PA levels were compared
to those at 12 months follow-up. The effect of time was
signiﬁcant on steps, mvpa and VMU (measured by both
Actigraph and MiniMod monitors) (Tables 3 and 4). For
instance, Actigraph stepcount was expected to be 16.9%
higher when assessed at baseline, compared to 12 months
follow-up (independently of age, climate conditions and
changes in FEV1% predicted, RV/TLC % predicted and
6MWT). Similarly mvpa values were 1.608 times as high
when assessed at baseline compared to 12 months follow-
up. On the other hand, levels of intensity and walktime were
the only two variables which were not independently asso-
ciated with time in multivariable analysis.
Effect of climate conditions on PA levels
The effect of climate conditions was overall minimal and
measure-speciﬁc. Rainfall (<1.7 hrs/day and 1.7–2.6 hrs/
day, compared to >2.6 hrs/day) was negatively associated
with average number of steps, as measured by both
Actigraph (B=−0.205 and −0.291, correspondingly) and
MiniMod (B=−0.258 and −0.354, correspondingly). For
example, presence of rainfall for up to 1.7 hrs/daily was
associated to 18.5% decrease in average Actigraph step
count, while raining for up to 2.6 hrs/daily was associated
to 25.2% decrease in number of steps, as measured by the
same monitor. Rainfall was also negatively associated with
walktime (B=−0.227 for up to 1.7 hrs/daily, and B=−0.309
for raining between 1.7 and 2.6 hrs/daily). As for VMU, a
deﬁnite negative association was established between rain-
fall and MiniMod measurements, but for Actigraph moni-
tor this association only tended to be statistically
signiﬁcant. On the contrary, rainfall had no impact on
mvpa and walk intensity (Tables 3 and 4).
As for the rest of climate factors, temperature estab-
lished only a negative, minimal effect on mvpa, as 1°C
increase of average temperature was associated with
approximately 3.7% decrease in mvpa measurements,
while it had no impact on other PA variables. Likewise,
day length had no signiﬁcant impact on any PA variable
measured by either Actigraph or MiniMod monitors
(Tables 3 and 4) and neither did any interactions between
temperature, day length and rainfall (data not shown). The
latter are not presented in the ﬁnal model, since their
inclusion did not improve the model ﬁt.
Difference of PA levels across study sites
The effect of recruitment site on PA measures was vari-
able. The most profound, positive effect was established
on mvpa. Athens was the study site with the strongest
impact, with mvpa values being higher by more than 4.7
times, while Edinburgh was the one with the smallest
impact, with mvpa values being higher by more than 1.5
times, compared to reference group. As for walktime and
intensity, London was the only study site which estab-
lished a minimal but signiﬁcant positive (for intensity)
and negative (for walktime) association with these PA
measures, while no effect of any study site was established
on steps or VMU measurements (Tables 3 and 4).
Population subanalysis
Two post-hoc subanalyses were conducted to test the
effect of time, climate conditions and study site on each
PA measure in the patient population who completed: 1)
only the baseline and the 6 months follow-up (N3=184),
and 2) only the baseline and the 12 months follow-up
(N4=168) (data not shown). In the ﬁrst analysis, time
was not independently associated with any PA measure,
apart for mvpa (B=0.458 for baseline visit vs 6 months
follow-up; p=0.008). The effect of climate conditions
remained minimal, while study site had an overall signiﬁ-
cant effect only on mvpa. In the second analysis, time
established an independent negative effect on all measures
of PA, apart from walktime and intensity. Moreover, rain-
fall was again the most important of climate variables,
posing a signiﬁcant negative effect on most PA measures,
while the effect of other ambient factors was minimal.
Dropouts
From the 236 patients who were initially recruited, only
157 patients had data for at least one activity monitor for
all visits, representing a 33% dropout rate over 1 year
across the whole studies (Figure 1). Overall, the subjects
who dropped out of the study at some point throughout the
12 months follow-up period had lower baseline PA levels
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Table 3 Estimated coefﬁcients and corresponding conﬁdence intervals of GLM regressors, calculated for each physical activity
parameter recorded by Dynaport MiniMod monitor
PA measures Predictor B Std error 95% CI p-value
AG steps Visit
-baseline 0.156 0.057 0.045–0.267 0.006
-6 months follow-up 0.056 0.074 -0.088–0.201 0.446
-12months follow-up Reference group Reference group Reference group Reference group
Center
-Athens 0.172 0.336 -0.031–0.375 0.097
-Edinburgh -0.229 0.104 -0.454 0.048
-Leuven -0.067 0.077 -0.218–0.084 0.387
-London -0.066 0.086 -0.233–0.102 0.443
-Groningen Reference group Reference group Reference group Reference group
Age -0.014 0.003 -0.012 <0.001
FEV1% predicted 0.007 0.001 0.005–0.010 <0.001
RV/TLC% predicted 0.003 0.002 -3E-4–0.007 0.095
QMVC -1.00E-4 0.002 -0.004–0.005 0.964
6MWD 0.003 2.00E-04 0.002–0.003 <0.001
Temperature 0.009 0.006 0.003–0.031 0.132
Daylength (hrs)
-<7.8 0.107 0.352 -1.378 0.761
-20.2 -0.002 0.073 -0.285 0.977
->12.4 Reference group Reference group Reference group Reference group
Rainfall (mm/day)
-<1.7 -0.205 0.102 -0.401 0.046
-4.3 -0.291 0.124 -0.487 0.019
->2.6 Reference group Reference group Reference group Reference group
AGmvpa Visit
-baseline 0.475 0.141 0.197–0.752 0.001
-6 months follow-up 0.021 0.168 -0.307–0.350 0.898
-12 months follow-up Reference group Reference group Reference group Reference group
Centre
-Athens 1.542 0.261 1.031–2.053 <0.001
-Edinburgh 0.455 0.288 -0.110–1.020 0.114
-Leuven 0.937 0.18 0.584–1.291 <0.001
-London 0.874 0.2 0.477–1.272 <0.001
-Groningen Reference group Reference group Reference group Reference group
Age -0.048 0.007 -0.029 <0.001
FEV1% predicted 0.008 0.003 0.003–0.014 0.003
RV/TLC% predicted -0.001 0.004 -0.009–0.007 0.847
QMVC -0.004 0.006 -0.016–0.009 0.535
6MWD 0.004 0.001 0.003–0.005 <0.001
Temperature -0.038 0.014 -0.056 0.007
Daylength (hrs)
-<7.8 -0.938 0.809 -3.172 0.246
-20.2 -0.282 0.158 -0.62 0.075
->12.4 Reference group Reference group Reference group Reference group
Rainfall (hrs/day)
-<1.7 0.009 0.237 -0.93 0.97
-4.3 -0.178 0.297 -1.164 0.549
->2.6 Reference group Reference group Reference group Reference group
(Continued)
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(step count, mvpa, VMU, PA intensity, walktime) as mea-
sured by either activity monitor (p<0.05). They also had a
lower baseline 6MWD (p=0.001), lower QMVC (p=0.003)
and worse quality of life, as suggested by the higher CCQ
scores (p=0.032), compared to those who did not dropout.
No difference was noted in exacerbation frequency
between the groups (p=0.67) and the groups were well
matched for age, BMI, FEV1% predicted and RV/TLC%
predicted. Weather conditions at baseline were also simi-
lar, apart from temperature which was approximately 2°C
lower in the group of patients who dropped out.
Discussion
In this multicenter, prospective, cohort study18 we inves-
tigated the effect of ambient climate factors on the pro-
gression of PA in COPD as measured by two validated,
commercially available PA monitors, at baseline, 6 months
and 12 months. There was a signiﬁcant effect of time with
a decline in almost every measure of physical activity over
12 months. The number of hours with rainfall daily had a
negative effect on most physical activity variables, but
otherwise analysis indicated hardly any associations
between PA and ambient conditions. The effect of study
site was most evident on mvpa, while for the rest of PA
measures it was variable and inconsistent.
Signiﬁcance of ﬁndings
The most important outcome of the study is establishing
that the passage of time itself is the most signiﬁcant pre-
dictor of PA decline over 12 months, as indicated by most
Actigraph and MiniMod monitor measures, especially
given the importance of physical activity as the strongest
predictor of all-cause mortality in COPD.29 Previous stu-
dies suggested that PA declines with time among COPD
patients;8,9 however, these were single-center studies, with
the follow-up period being much longer. In our study, the
decline of PA applied to all centers, despite the patients
having (by design) a wide range in baseline characteristics,
including age, FEV1, climate conditions, 6MWD and PA
and, thus, this is a ﬁnding with positive implications for
Table 3 (Continued).
PA measures Predictor B Std error 95% CI p-value
AGVMU Visit
-baseline 0.156 0.046 0.064–0.246 0.001
-6 months follow-up 0.057 0.06 -0.059–0.174 0.335
-12 months follow-up Reference group Reference group Reference group Reference group
Center
-Athens 0.022 0.083 -0.141–0.184 0.795
-Edinburgh -0.052 0.094 -0.237–0.133 0.581
-Leuven -0.026 0.062 -0.148–0.097 0.68
-London -0.058 0.069 -0.193–0.076 0.394
-Groningen Reference group Reference group Reference group Reference group
Age -0.012 0.003 -0.01 <0.001
FEV1% predicted 0.006 0.001 0.004–0.008 <0.001
RV/TLC% predicted 0.001 0.002 -0.002–0.004 0.364
QMVC -0.003 0.002 -0.007–0.001 0.154
6MWD 0.002 2.00E-04 0.001–0.002 <0.001
Temperature 0.007 0.005 -0.002–0.017 0.119
Daylength (hrs)
-<7.8 -0.138 0.287 -1.124 0.631
-20.2 0.002 0.059 -0.229 0.967
->12.4 Reference group Reference group Reference group Reference group
Rainfall (hrs/day)
-<1.7 -0.163 0.084 -0.329 0.051
-4.3 -0.186 0.101 -0.397 0.067
->2.6 Reference group Reference group Reference group Reference group
Abbreviations: RV/TLC%, ratio of residual volume to total lung volume percentage predicted; GLM, generalized linear model; PA, physical activity; Std, standard; AG,
Actigraph GT3X monitor; RV, residual volume; TLC, total lung capacity; QMVC, quadriceps maximal voluntary contraction; mvpa, moderate to vigorous physical activity;
VMU, vector magnitude units; E-4, 10−4.
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Table 4 Estimated coefﬁcients and corresponding conﬁdence intervals of GLM regressors, calculated for each physical activity
parameter recorded by Dynaport MiniMod monitor
PA measures Predictor B coefﬁcients Std error 95% CI p-value
MM steps Visit
-baseline 0.029 0.059 0.086–0.145 0.033
-6 months follow-up -0.08 0.077 -0.232–0.072 0.301
-12 months follow-up Reference group Reference group Reference group Reference group
Center
-Athens 0.127 0.107 -0.081–0.336 0.232
-Edinburgh -0.237 0.124 -0.479–0.005 0.055
-Leuven -0.054 0.081 -0.212–0.104 0.503
-London -0.156 0.093 -0.337–0.026 0.093
-Groningen Reference group Reference group Reference group Reference group
Age -0.006 0.003 -0.013–4.4E-5 0.048
FEV1% predicted 0.006 0.001 0.004–0.009 <0.001
RV/TLC% predicted 0.003 0.002 -0.001–0.007 0.11
QMVC -2.10E-4 0.003 -0.005–0.005 0.932
6MWD 0.003 3.00E-4 0.002–0.003 <0.001
Temperature 0.006 0.006 -0.006–0.018 0.313
Daylength (hrs)
-<7.8 -0.051 0.354 -0.746–0.643 0.885
-20.2 -0.091 0.076 -0.240–0.058 0.23
->12.4 Reference group Reference group Reference group Reference group
Rainfall (hrs/day)
-<1.7 -0.258 0.105 -0.412 0.014
-4.3 -0.354 0.128 -0.5 0.006
->2.6 Reference group Reference group Reference group Reference group
MM walktime Visit
-baseline 0.026 0.055 -0.081–0.133 0.632
-6 months follow-up -0.09 0.072 -0.231–0.051 0.21
-12 months follow-up Reference group Reference group Reference group Reference group
Center
-Athens 0.107 0.099 -0.440–0.011 0.278
-Edinburgh -0.214 0.115 -0.188–0.104 0.062
-Leuven -0.042 0.075 -0.334 0.57
-London -0.169 0.085 -0.082–0.133 0.048
-Groningen Reference group Reference group Reference group Reference group
Age -0.005 0.003 -0.0109 0.048
FEV1% predicted 0.005 0.001 0.003–0.008 <0.001
RV/TLC% predicted 0.003 0.002 -0.001–0.006 0.147
QMVC 0.002 0.002 -0.003–0.067 0.396
6MWD 0.002 2.00E-4 0.002–0.003 <0.001
Temperature 0.006 0.006 -0.005–0.016 0.312
Daylength (hrs)
-<7.8 -0.027 0.328 -0.669–0.615 0.934
-20.2 -0.098 0.07 -0.235–0.040 0.165
->12.4 Reference group Reference group Reference group Reference group
Rainfall (hrs/day)
-<1.7 -0.227 0.097 -0.382 0.02
-4.3 -0.309 0.118 -0.462 0.009
->2.6 Reference group Reference group Reference group Reference group
(Continued)
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Table 4 (Continued).
PA measures Predictor B coefﬁcients Std error 95% CI p-value
MM intensity Visit
-baseline 0.015 0.015 -0.015–0.045 0.333
-6 months follow-up 0.009 0.02 -0.030–0.048 0.648
-12 months follow-up Reference group Reference group Reference group Reference group
Center
-Athens 0.043 0.027 -0.011–0.097 0.118
-Edinburgh 0.035 0.033 -0.028–0.099 0.279
-Leuven -0.027 0.021 -0.067–0.014 0.198
-London 0.081 0.024 0.035–0.127 0.001
-Groningen Reference group Reference group Reference group Reference group
Age -0.006 8.00E-4 -0.003 <0.001
FEV1% predicted 0.002 3.00E-4 0.001–0.002 <0.001
RV/TLC% predicted -3.50E-4 5.00E-4 -0.001–0.001 0.476
QMVC -0.001 6.00E-4 -0.002914 0.036
6MWD 4.80E-4 6.50E-5 3.6E-4–0.001 <0.001
Temperature -7.50E-5 0.002 -0.003–0.003 0.961
Daylength (hrs)
-<7.8 0.043 0.092 -0.137–0.222 0.642
-20.2 -0.004 0.019 -0.042–0.033 0.817
->12.4 Reference group Reference group Reference group Reference group
Rainfall (hrs/day)
-<1.7 -0.012 0.027 -0.065–0.042 0.668
-4.3 -0.035 0.033 -0.100–0.029 0.284
->2.6 Reference group Reference group Reference group Reference group
MMVMU Visit
-baseline 0.085 0.056 0.024–0.194 0.026
-6 months follow-up -0.01 0.072 -0.152–0.131 0.885
-12 months follow-up Reference group Reference group Reference group Reference group
Center
-Athens 0.129 0.1 -0.067–0.325 0.197
-Edinburgh -0.065 0.116 -0.293–0.163 0.576
-Leuven -0.114 0.076 -0.263–0.035 0.133
-London 0.002 0.087 -0.168–0.172 0.983
-Groningen Reference group Reference group Reference group Reference group
Age -0.016 0.003 -0.012 <0.001
FEV1% predicted 0.008 0.001 0.005–0.010 <0.001
RV/TLC% predicted 0.001 0.002 -0.003–0.004 0.699
QMVC -0.005 0.002 -0.00951 0.03
6MWD 0.003 2.00E-4 0.002–0.003 <0.001
Temperature 0.001 0.006 -0.010–0.012 0.83
Daylength (hrs)
-<7.8 -0.258 0.332 -0.909–0.394 0.438
-20.2 -0.066 0.07 -0.203–0.070 0.342
->12.4 Reference group Reference group Reference group Reference group
Rainfall (hrs/day)
-<1.7 -0.238 0.098 -0.388 0.016
-4.3 -0.339 0.119 -0.468 0.005
->2.6 Reference group Reference group Reference group Reference group
Abbreviations: QMVC, quadriceps maximal voluntary contraction; RV/TLC%, ratio of residual volume to total lung volume percentage predicted; E-4, 10-4; Ε-5, 10-5.
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future studies in COPD patients, suggesting that PA can be
used as an outcome measure over periods as short as 1 year.
Surprisingly two PA measures, namely walktime and inten-
sity, although signiﬁcantly declining over the 12-month
period, were not signiﬁcantly associated with time per se
in multivariate analysis. This may be because 12 months are
not long enough for elapsed time to establish its indepen-
dent effect on these two measures, but this is a hypothesis
that will need further investigation. In any case, establishing
which PAmeasures decline over time provides guidance for
early interventions to preserve physical activity levels
among COPD patients and for the design of studies to
evaluate interventions to enhance or preserve physical
activity.
The effect of climate factors on PAwas measure-speciﬁc
overall. Rainfall hours were the main climate variable which
posed a signiﬁcant negative effect on average number of
steps, walktime and VMU, and this effect was only evident
over the 12 months follow-up. These ﬁndings are consistent
with a previous study where high levels of rain (more than 10
mm/daily) resulted to decreased average number of steps
daily,30 among COPD individuals. Some previously pub-
lished, single-center studies indicated that daily temperature
might also be a signiﬁcant predictor of daily PA, with higher
temperature levels being associated with greater PA.14,15,30 In
our study, however, temperature established only a minimal,
negative effect on mvpa, a result that is difﬁcult to explain,
since this association has not been assessed before. During
the 12 months follow-up period, the recorded temperatures in
different study sites ranged from −4.5°C (in Leuven) to
approximately 38°C (in Athens), so the lack of an impact
of temperature on several PA measures cannot be attributed
to the narrow range of temperature values included in the
analysis. It is likely that our use of a weekly average may
have masked the potential effects of temperature on PA at the
daily level. Furthermore, no effect was evident for day
length, nor its interactions with any other climate variable.
Currently, the published studies14,15,31 looking at the effect of
climate on PA in COPD are few and they are not without
limitations. In the most recent study, Alahmari et al investi-
gated the effect of weather data (temperature, rainfall, sun-
shine), environmental particulate matter <10 μm (PM10) and
ozone levels on PA using pedometers, in a cohort of COPD
patients who were followed up daily. The authors found step
count to be lower on colder and overcast days, while there
was also a negative impact of atmospheric PM10 and ozone
levels, on step count.14 However, this study involved a smal-
ler number of patients, with a very wide variation in follow-
up period ranging from 1 month to almost 21 months, while
results were not adjusted for age, FEV1% predicted and other
disease severity measures. In the study of Moy et al, where
season was found to have some effect on step count, the
cohort was made up mostly of male patients, the follow-up
period was short, while there were no objective measure-
ments regarding climatic conditions, such as temperature or
sunshine, to deﬁne the seasons.15 Maximum temperature,
sunshine and day length were positive independent predic-
tors of daily PA in another study among elderly individuals;
nevertheless, these were subjects without COPD, while the
PA and climate data were recorded for a very short period.31
In the most similar study in the ﬁled, minimum and max-
imum temperature, daylight duration and humidity had some
impact on PA among COPD patients; nevertheless, this study
included a small patient population, while duration of follow-
up was shorter and temperature ranges smaller.32 In conclu-
sion, the signiﬁcant effect of rainfall, but not of any other
climate condition, on several measures of PA levels in our
study, after controlling for elapsed time and other major
determinants of disease severity among COPD patients, indi-
cate that climate factors are probably not major determinants
of PA levels in this population.
To the authors’ knowledge, the current study is the
only published one that investigated the effect of climate
conditions on several PA parameters, measured using two
different activity monitors worn simultaneously by
patients. In other similar studies in the ﬁeld, the main
measure used was step count.14,15,30 Although the accu-
racy of both monitors (Actigraph and MiniMod) in mea-
suring PA among COPD patients is similar and has been
previously conﬁrmed,25,26 it might be the case that some
measures of PA may be less sensitive in detecting any
impact of climate conditions than others, especially since
this effect seems to be present, but not very profound.
However, this is an assumption that needs to be further
investigated.
The effect of study site on PA levels was variable and
the interpretation of this result lies probably beyond dis-
ease severity. The PA measure mostly affected by study
site was mvpa, while for step count and VMU, no effect of
study site was observed. Previously published data indi-
cate that several socio-cultural, socio-economic and envir-
onmental factors, which could vary signiﬁcantly in
different communities, may determine the level of PA in
adults.33,34 Micro- and macroenvironment in the area of
living seems to be an important determinant of PA with
high street connectivity, high neighborhood walkability,
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availability and proximity of transport system being posi-
tively associated with daily PA. Likewise, adverse street
characteristics, such as lack of sidewalks and streetlights
are negatively associated with PA among adults.35,34
Unfortunately, these environmental and neighborhood
data were not available in our study, so they were not
controlled for; however, since they could cause some
differences between sites, selecting PA variables that
seem to be less affected by study site, such as step count
or VMU as outcome measures, could possible decrease
diversity in studies with multicenter protocol.
Nevertheless, even if these site differences exist at base-
line, they are unlikely to change over the time course of a
clinical trial.
Another interesting observation was that baseline tem-
perature was approximately 2°C lower in the group of
patients that dropped out of the study. These patients also
had lower baseline PA, as established by both activity
monitors and lower exercise capacity, lower QMVC and
higher CCQ scores, compared to the ones who completed
the study. These characteristics mirror the ﬁndings in
pulmonary rehabilitation studies where those patients
who drop out have worse exercise capacity, are more
breathless, have poorer health-related quality of life and
weaker quadriceps strength.37,36 Whether these patients
might also be more sensitive to the effect of environmental
conditions is yet to be investigated.
Methodological issues
The current study has several strengths, but also carries
some limitations, as expected. It is a part of a large, multi-
center project, conducted in different geographical sites,
which collected a large amount of PA and climate data
using two previously validated activity monitors, over
three time points, among COPD patients with a wide
range of disease severity.18 Data were all centrally col-
lected and checked, based on predeﬁned rules, in order to
minimize site variability due to potential methodological
bias. Unfortunately, the analysis of climate was limited by
the availability of data, since number of hours of sunshine
per day was not available for all centers, and other factors
such as humidity or pollution levels were not available for
any site. Furthermore, severity of rainfall, measured in mm
per hour was not analyzed, as these data were not available
for every site. Another limitation is the use of weekly
averages of climate variables, which may have decreased
the daily effect of climate variation on PA. Moreover, the
season of patient recruitment was not analyzed, since not
only in some centers the seasonal differences in climate
are less profound compared to other centers, but also in
real life there is a gradual transition from one season to the
next, so grouping patients by season would be arbitrary;
the interaction of temperature with day length was used
instead, as an objective surrogate of seasonal effect,
although it remained a non-signiﬁcant factor in statistical
analysis. Finally, it is unfortunate but expected that
patients dropped out of the study after their initial or 6-
month visit. In the single-center study of Watchki et al ,
the dropout rate was 20%,9 which is lower than the present
study (33%), but still a signiﬁcant number, while in similar
studies conducted among COPD patients who undergo
pulmonary rehabilitation, dropout rates may be as high as
30–40%.37,36 In any case this is a ﬁnding that has to be
accounted for in future studies, especially in sample size
calculations.
Conclusion
We have demonstrated a decline in PA in people with
COPD over 1-year follow-up, with elapsed time itself
being an independent predictor of this change, in the
absence of signiﬁcant decline in FEV1 or 6MWD. If PA
declines more consistently than other clinically important
measures in COPD population, such as exercise capacity
or lung function, it may represent a more sensitive out-
come measure for use when designing future studies in
COPD. Overall, the effect of climate on PA decline was
inconsistent, although more hours with rainfall during the
day were associated with lower PA and cooler tempera-
tures seemed to be associated with an increased dropout
rate. Since the background effects of time on PA over 6
months are fairly small, we can conclude that a 6 months
follow-up period for a trial would be reasonable, without
the need to require 12 months, so that climate conditions
are broadly matched between baseline and study end. In
this case mvpa is probably a less appropriate PA variable
to measure, since it is the only one affected by elapsed
time, ambient conditions and study site, during follow-up
periods shorter than a year. These ﬁndings should be
useful in the design of future multicenter studies using
PA as an outcome measure.
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